Join the club for FREE to access the whole archive and other member benefits.

Poietis' bioprinting platform designs inexpensive human implants efficiently


Key points from article :

Poietis aims to address issues of implantable tissues, such as standardization, product reproducibility, and scaling up.

Fabien Guillemot (CEO of Poietis) and Bruno Brisson (co-founder of Poietis) detail the Next Generation Bioprinting (NGB) platform.

Printing and manufacturing phase is automated and robotized.

Benefits: affordable treatment; controlling architecture to increase functionality

Apart from skin, NGB platform can be used for other cell and tissue types.

Equipped with Stäubli’s robotic arm for moving the tissue under construction from one printing head to another.

Skin substitutes included both epidermis and dermis — not feasible at the artisanal level.

Before automation, it took about 8-9 hours to manufacture a 40 cm2 square of skin; while it takes only 3-4 hours after automation.

Phase I–II project probably in dozens of patients with wounds, small burns and traumatic wounds.

World’s first clinical trial of bioprinted skin graft will start in 2022 at the University Hospital of Marseille.

Its automated 4D technology can manufacture different implantable tissues

Mentioned in this article:

Click on resource name for more details.

Bruno Brisson

Co-founder and Chief Business Officer at Poietis

Fabien Guillemot

Founder and CEO of Poietis


Biotechnology company to produce real human tissues